Merck KGaA (OTCPK:MKKGY) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Florian Schraeder - Head of Investor Relations Belén Garijo López - Chair of Executive Board & CEO Helene von Roeder - CFO & Member of Executive Board Danny Bar-Zohar - Member of the Executive Board & CEO of Healthcare Kai Beckmann - Deputy CEO of Electronics & Member of the Executive Board Jean Wirth - Member of the Executive Board & CEO Life Science Conference Call Participants Matthew Weston - UBS Investment Bank, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Shyam Kotadia - Goldman Sachs Group, Inc., Research Division Charles Pitman - Barclays Bank PLC, Research Division Peter Verdult - BNP Paribas, Research Division Oliver Metzger - ODDO BHF Corporate & Markets, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
Investors interested in Medical - Drugs stocks are likely familiar with Merck KGaA (MKKGY) and United Therapeutics (UTHR). But which of these two stocks is more attractive to value investors?
Investors interested in Medical - Drugs stocks are likely familiar with Merck KGaA (MKKGY) and Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Merck KGaA (MKKGY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.